NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab

Cardio-Oncology
doi 10.1186/s40959-019-0039-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Prognostic Value of HER2 to CEP17 Ratio on Fluorescence in Situ Hybridization Ratio in Patients With Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Trastuzumab

Oncologist
Cancer ResearchMedicineOncology
2020English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Trastuzumab in Combination With AT-101 Induces Cytotoxicity and Apoptosis in Her2 Positive Breast Cancer Cells

Future Oncology
MedicineCancer ResearchOncology
2020English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Efficacy of Neoadjuvant Therapy With Trastuzumab Concurrent With Anthracycline- And Nonanthracycline-Based Regimens for HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2011English

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy